Evidence map›Paper›PMID 37908774›Full record

ArticleActa naturae

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens.

M K Ibragimova, E A Kravtsova, M M Tsyganov, N V Litviakov

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

M K IbragimovaCancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, 634009 Russian Federation.
E A KravtsovaCancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, 634009 Russian Federation.
M M TsyganovCancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, 634009 Russian Federation.
N V LitviakovCancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, 634009 Russian Federation.
Russian Academy of Sciences · RUSiberian State Medical University · RUTomsk National Research Medical Center · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Critical evaluation of how and when to include anthracyclines in preoperative chemotherapy is becoming more relevant in an era when the molecular genetic approach not only allows for the development of biologically targeted therapeutics, but also implies the ability to select the patients likely to benefit from certain cytotoxic agents. Changes in the copy number aberration (CNA) landscape of luminal B HER2- negative (HER2-) breast cancer (BC) during anthracycline-based neoadjuvant chemotherapy (NAC) regimens were studied in order to identify groups of potential CNA markers of objective response and CNA markers for predicting the development of hematogenous metastasis. Comparison of CNA frequencies depending on the response to NAC showed that objective response was observed in a larger number of deletions in the 11q22.3 and 11q23.1 loci (

Indexed as

anthracycline-based regimensbreast cancerCNA landscapeneoadjuvant chemotherapyprognosis

Identifiers

PMID37908774
PMCPMC10615187
OpenAlexW4388105632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.